open access

Vol 93, No 4 (2022)
Research paper
Published online: 2021-05-19
Get Citation

Role of tumor location on high-grade serous ovarian cancer prognosis

Seval Ay1, Deniz Tataroğlu Özyükseler1, Mustafa Başak1, Özgecan Dülgar1, Serdar Arıcı1, Mahmut Emre Yıldırım1, Mahmut Gümüş1
·
Pubmed: 34105739
·
Ginekol Pol 2022;93(4):284-289.
Affiliations
  1. Medical Oncology Clinic, Istanbul Medeniyet University, Turkey

open access

Vol 93, No 4 (2022)
ORIGINAL PAPERS Gynecology
Published online: 2021-05-19

Abstract

Objectives: Ovarian cancer is associated with the highest mortality of gynecologic cancers. Epidemiological and genetic factors of ovarian cancer development are clearly defined but prognostic factors have not been adequately identified. Right and left ovarian cancers seem to act different behaviors at high-grade serous ovarian cancer (HGSOC) prognosis. The aim of this study is to explain this prognostic role of its sidedness. The aim of this study is to explain this prognostic role of its sidedness. Material and methods: We reviewed 160 consecutive patients with Figo stage 1-3 HGSOCs and undergone surgery at two high-volume hospitals. Prognostic effects of primary tumor location onset were evaluated in terms of 5-year disease free survival and overall survival rate. Results: One hundred-sixty patients with ovarian cancer records were analyzed using the Kaplan-Meier method, that demonstrated a significant difference in the 5-year disease-free survival rates between right and left-sided cancers for all stages (44.6% vs 78.5%, p < 0.001). Also, there was significant difference in the 5-year overall survival rates between the two groups (71.1% vs 91.9%, p = 0.020). Conclusions: Tumor location within the HGSOC seems to be a compelling prognostic factor ovarian cancer. Further prospective studies are needed in order to support our hypothesis.

Abstract

Objectives: Ovarian cancer is associated with the highest mortality of gynecologic cancers. Epidemiological and genetic factors of ovarian cancer development are clearly defined but prognostic factors have not been adequately identified. Right and left ovarian cancers seem to act different behaviors at high-grade serous ovarian cancer (HGSOC) prognosis. The aim of this study is to explain this prognostic role of its sidedness. The aim of this study is to explain this prognostic role of its sidedness. Material and methods: We reviewed 160 consecutive patients with Figo stage 1-3 HGSOCs and undergone surgery at two high-volume hospitals. Prognostic effects of primary tumor location onset were evaluated in terms of 5-year disease free survival and overall survival rate. Results: One hundred-sixty patients with ovarian cancer records were analyzed using the Kaplan-Meier method, that demonstrated a significant difference in the 5-year disease-free survival rates between right and left-sided cancers for all stages (44.6% vs 78.5%, p < 0.001). Also, there was significant difference in the 5-year overall survival rates between the two groups (71.1% vs 91.9%, p = 0.020). Conclusions: Tumor location within the HGSOC seems to be a compelling prognostic factor ovarian cancer. Further prospective studies are needed in order to support our hypothesis.

Get Citation

Keywords

disease free survival; high-grade serous ovarian cancer; left and right side cancers; overall survival; prognostic values; tumor location

About this article
Title

Role of tumor location on high-grade serous ovarian cancer prognosis

Journal

Ginekologia Polska

Issue

Vol 93, No 4 (2022)

Article type

Research paper

Pages

284-289

Published online

2021-05-19

Page views

5406

Article views/downloads

1469

DOI

10.5603/GP.a2021.0123

Pubmed

34105739

Bibliographic record

Ginekol Pol 2022;93(4):284-289.

Keywords

disease free survival
high-grade serous ovarian cancer
left and right side cancers
overall survival
prognostic values
tumor location

Authors

Seval Ay
Deniz Tataroğlu Özyükseler
Mustafa Başak
Özgecan Dülgar
Serdar Arıcı
Mahmut Emre Yıldırım
Mahmut Gümüş

References (19)
  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359–E386.
  2. National Institutes of Health. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Statistical summaries: cancer stat fact sheets (ovary) and cancer statistics review (CSR), 1975–2013.
  3. P P, Campbell K, Mishell D. Jr. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989; 74: 926–921.
  4. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017; 14(1): 9–32.
  5. Bilimoria KY, Palis B, Stewart AK, et al. Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum. 2008; 51(2): 154–161.
  6. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11): 1350–1356.
  7. Brewster DH, Horner MJD, Rowan S, et al. Left-sided excess of invasive cutaneous melanoma in six countries. Eur J Cancer. 2007; 43(18): 2634–2637.
  8. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence – SEER 17 Regs Limited-Use, November 2005 Sub (1973–2003 varying) – Linked to county attributes – Total US, 1969–2003 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission. www.seer.cancer.gov.
  9. CAPPELLO F, BELLAFIORE M, PALMA A, et al. Study of axillary lymph node asymmetry in a female population. Journal of Anatomy. 2001; 199(5): 617–620.
  10. Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer. 1993; 71(4 Suppl): 1534–1540.
  11. Esselen KM, Cronin AM, Bixel K, et al. Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol. 2016; 2(11): 1427–1433.
  12. Roychoudhuri R, Putcha V, Møller H. Cancer and laterality: a study of the five major paired organs (UK). Cancer Causes Control. 2006; 17(5): 655–662.
  13. Dane S, Borekci B, Kadanali S. Right-sided lateralisation of ovarian cancer and right bias asymmetry for involved pelvic lymph nodes by ovarian cancer cells. Laterality. 2008; 13(5): 393–402.
  14. DANE E. CELL-MEDIATED IMMUNE HYPERSENSITIVITY IS STRONGER IN THE LEFT SIDE OF THE BODY THAN THE RIGHT IN HEALTHY YOUNG SUBJECTS. Perceptual and Motor Skills. 2001; 93(6): 329.
  15. Gontova IA, Abramov VV, Kozlov VA. Asymmetry of delayed type hypersensitivity reaction in mice. Bull Exp Biol Med. 2003; 135(1): 67–69.
  16. Erdem T, Dane S, Kadi M. Cell-mediated immune hypersensitivity is stronger on non- involved side than involved side in patients with herpes zoster. International Journal of Neuroscience. 2003; 113: 1086–1081.
  17. Wray C, Ziogas A, Hinojosa M, et al. Tumor Subsite Location Within the Colon Is Prognostic for Survival After Colon Cancer Diagnosis. Diseases of the Colon & Rectum. 2009; 52(8): 1359–1366.
  18. Benedix F, Schmidt U, Mroczkowski P, et al. Study Group "Colon/Rectum Carcinoma (Primary Tumor)". Colon carcinoma--classification into right and left sided cancer or according to colonic subsite?--Analysis of 29,568 patients. Eur J Surg Oncol. 2011; 37(2): 134–139.
  19. Stone JM, Cruickshank DG, Sandeman TF, et al. Laterality, maldescent, trauma and other clinical factors in the epidemiology of testis cancer in Victoria, Australia. Br J Cancer. 1991; 64(1): 132–138.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl